Cancer Biopsy Market Forecasts to 2030 – Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography

Cancer Biopsy Market Forecasts to 2030 – Global Analysis By, Product (Instruments, Kits and Consumables and Other Products), Type (Tissue Biopsies, Liquid Biopsies, Surgical Biopsies and Other Types), Application, End User and By Geography

According to Stratistics MRC, the Global Cancer Biopsy Market is accounted for $26.6 billion in 2023 and is expected to reach $95.4 billion by 2030 growing at a CAGR of 20% during the forecast period. A cancer biopsy is a medical procedure involving the removal and examination of a small tissue sample from a suspicious or abnormal growth, lump, or lesion to determine the presence, nature, and characteristics of cancer cells. Cancer biopsies are fundamental to providing accurate and detailed information for oncologists and healthcare professionals, helping them formulate precise diagnoses and develop tailored treatment plans based on the unique characteristics of each patient's cancer.

According to USA breast cancer statistics, about one in every eight women in the USA develops invasive breast cancer.

Market Dynamics:

Driver:

Rising cancer incidence

Cancer continues to be a global health concern, with increasing numbers of individuals being diagnosed with various types of cancer due to various factors such as aging populations, lifestyle changes, environmental exposures, and genetic predisposition. As the number of cancer cases increases, the demand for accurate and timely cancer diagnosis also grows. Biopsy procedures play a crucial role in confirming cancer diagnoses by obtaining tissue samples for pathological analysis. Therefore, rising cancer incidence is a significant factor accelerating market demand.

Restraint:

High cost

The high cost of diagnosis is one of the main factors anticipated to impede the growth of the global cancer biopsy market. Cancer diagnostic tests are highly costly, which puts additional financial strain on patient families. Thus, these tests are not affordable for middle-class patient population that is not covered under any insurance. Additionally, a number of private insurance companies do not pay for cancer diagnosis-related expenses, which means that the high cost of diagnosis restricts the use of cancer screening technologies.

Opportunity:

Technological advancements

Technological advancements have led to the development of minimally invasive biopsy techniques such as fine needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These techniques use smaller incisions or needles to obtain tissue samples, reducing patient discomfort, minimizing the risk of complications, and enabling faster recovery compared to traditional open surgical biopsies. These factors enhance market demand.

Threat:

Lack of awareness

In certain regions or demographic segments, there is a lack of sufficient awareness among both the general population and healthcare professionals about the critical role of biopsies in cancer diagnosis. Patients may not fully comprehend the importance of biopsy procedures in determining the nature and characteristics of tumours, leading to hesitancy or reluctance to undergo these essential diagnostic tests. As a result, a lack of awareness is a significant restraint hampering the market.

Covid-19 Impact

The emergence of COVID-19 had a significant impact on the cancer biopsy market. Hospital visits were severely restricted during the early stages of the pandemic as a result of social distancing measures; only patients with emergencies were permitted, which had a negative effect on the market's expansion. Moreover, following the pandemic, there was a rise in the adoption of new technologies, which opened up new prospects for the market under study.

The surgical biopsies segment is expected to be the largest during the forecast period

The surgical biopsies segment is estimated to hold the largest share. A surgical biopsy involves the removal of a tissue sample through an incision or during a surgical procedure. This method is commonly employed when larger tissue specimens are needed for thorough examination, allowing pathologists to analyze the tumour’s characteristics, grade, and extent of spread. In cancer biopsies, surgical biopsies are frequently utilized for tumours located in deep or challenging-to-access areas, where obtaining an adequate tissue sample is crucial for accurate diagnosis and treatment planning.

The instruments segment is expected to have the highest CAGR during the forecast period

The instruments segment is anticipated to have lucrative growth during the forecast period. Instruments play a pivotal role in facilitating precise and effective biopsy procedures, contributing to accurate cancer diagnoses and treatment decisions. These instruments encompass a wide range of devices used to obtain tissue samples for examination, including traditional biopsy needles, biopsy forceps, and specialized tools designed for minimally invasive procedures. Additionally, advanced imaging instruments such as ultrasound, MRI, and CT scanners are integral to guiding clinicians to the specific site for biopsy, ensuring targeted and accurate sampling.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to rapid advancements in healthcare infrastructure and a growing focus on early cancer detection and treatment. With a rising prevalence of cancer cases in countries like China, India, and Japan, there is an increasing demand for biopsy procedures as a crucial component of the diagnostic pathway. Moreover, the region's commitment to improving cancer care and fostering medical research positions it as a key contributor to the global cancer biopsy market.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to advanced healthcare infrastructure, a high prevalence of cancer cases, and a robust focus on technological innovation. In North America, various biopsy techniques, including surgical, needle, and liquid biopsies, are widely employed to obtain precise and comprehensive information for cancer diagnosis and treatment planning. Additionally, the adoption of cutting-edge imaging technologies, molecular diagnostics, and minimally invasive biopsy procedures underscores the region's commitment to enhancing diagnostic accuracy and patient outcomes.

Key players in the market

Some of the key players in the Cancer Biopsy Market include Becton, Dickinson and Company, Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Illumina, Inc., Myriad Genetics, Inc., Hologic, Inc., Neo Genomics, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., QIAGEN N.V. and Sysmex Corporation.

Key Developments:

In May 2023, Partnership between Thermo Fisher Scientific and BRIN to enable and enhance the country's national research and innovation infrastructure and capability.

In March 2023, Thermo Fisher Scientific, the world leader in serving science, and Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.

In Jan 2023, Philips a global leader in health technology, and Masimo, a global medical technology company, announced an expansion of their partnership to augment patient monitoring capabilities in home telehealth applications with the Masimo W1™ advanced health tracking watch.

Products Covered:
• Instruments
• Kits and Consumables
• Other Products

Types Covered:
• Tissue Biopsies
• Liquid Biopsies
• Surgical Biopsies
• Other Types

Applications Covered:
• Cervical Cancer
• Colorectal Cancer
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Skin Cancer
• Kidney Cancer
• Blood Cancer
• Ovarian Cancer
• Liver Cancer
• Pancreatic Cancer
• Other Applications

End Users Covered:
• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments

- Strategic recommendations for the new entrants

- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030

- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

- Strategic recommendations in key business segments based on the market estimations

- Competitive landscaping mapping the key common trends

- Company profiling with detailed strategies, financials, and recent developments

- Supply chain trends mapping the latest technological advancements